COMMUNIQUÉS West-GlobeNewswire

Quantity of shares in Nexstim Plc after completion of the first phase in reducing the quantity of shares
23/11/2018
Company announcement, Helsinki, 23 November 2018 at 21:00 Quantity of shares in Nexstim Plc after completion of the first phase in reducing the quantity of shares The Extraordinary General Meeting of Nexstim Plc (NXTMH: [...]
Milestone Scientific Announces Recent Presentations Featuring The Wand® STA
23/11/2018
LIVINGSTON, N.J., Nov. 23, 2018 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS) , a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced [...]
Abattis Bioceuticals Acquires Proprietary Genetic Strain Bank
23/11/2018
VANCOUVER, British Columbia, Nov. 23, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp (the “ Company ” or “ Abattis ”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that it has entered into a definitive agreement (the [...]
Mandatory notification of trade
23/11/2018
Valborg Godal Vold, COO of Vistin Pharma ASA, and a primary insider, has on 18 September 2018 sold 50,000 shares in Vistin Pharma ASA at an average price of NOK 10.58 per share. Following this sale Valborg Godal Vold [...]
Oral semaglutide demonstrates favourable cardiovascular safety profile and significant reduction in cardiovascular death and all-cause mortality in people with type 2 diabetes in the PIONEER 6 trial
23/11/2018
Bagsværd, Denmark, 23 November 2018 - Novo Nordisk today announced the headline results from the last global phase 3a trial, PIONEER 6, for oral semaglutide, an investigational GLP-1 analogue taken once daily as a [...]
ATW Tech Increases Its Revenues by 24% for Revenues of $3.1 Million for Its Third Quarter of 2018
23/11/2018
MONTREAL, Nov. 23, 2018 (GLOBE NEWSWIRE) -- ATW Tech Inc. (the “Company”) (TSX-V: ATW) announces its financial results for its third quarter ended September 30, 2018. For its third quarter of 2018, the Company announced [...]
ATW Tech annonce des revenus en hausse de 24% pour 3,1 millions $ pour son troisième trimestre 2018
23/11/2018
MONTRÉAL, 23 nov. 2018 (GLOBE NEWSWIRE) -- ATW Tech Inc. (la « Société ») (TSX-V : ATW) annonce aujourd'hui ses résultats pour son troisième trimestre terminé le 30 septembre 2018. Pour son troisième trimestre 2018, la [...]
Aura Closes Strategic Investment Into HolyCanna, Bolstering International Strategy
23/11/2018
TORONTO, Nov. 23, 2018 (GLOBE NEWSWIRE) -- Aura Health Inc. (the " Company " or “ Aura ”) ( CSE:BUZZ ) is pleased to announce the closing of its previously announced letter of intent (“ LOI ”) to secure a majority (54 [...]
Aleafia Closes Transactions with Serruya Private Equity
23/11/2018
Transactions Positions Aleafia as Major Supplier, Retailer of Adult-use Cannabis TORONTO, Nov. 23, 2018 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSXV: ALEF; OTCQX: ALEAF, FRA: ARAH) (“Aleafia“ or the “Company“) is [...]
Aleafia to Release Q3 Results on November 26
23/11/2018
TORONTO, Nov. 23, 2018 (GLOBE NEWSWIRE) -- Aleafia Health Inc. ( TSXV: ALEF; OTCQX: ALEAF, FRA: ARAH ) (“ Aleafia “) or (the “ Company “), a highly differentiated cannabis company with major cannabis cultivation and [...]
Immunicum AB (publ) Publishes Prospectus in Connection with Rights Issue and Directed Issue
23/11/2018
Press Release 23 November 2018 NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, [...]
BLOCK LISTING SIX MONTHLY RETURN
23/11/2018
BLOCK LISTING SIX MONTHLY RETURN November 23, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) Name of applicant : Shire plc Name of scheme: Shire Sharesave Scheme Period of return: From: May 23, 2018 To: November 22, 2018 [...]
Rule 2.9 Announcement
23/11/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 23 November 2018 [...]
Curetis Announces Financial Results for the First Nine Months of 2018
23/11/2018
Curetis Announces Financial Results for the First Nine Months of 2018 - Total year-on-year revenue growth of 43% globally, 207% in EMEA direct selling markets - Initial traction in U.S. market after Unyvero launch - [...]
Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease
23/11/2018
Luxturna* (voretigene neparvovec) is the first gene therapy to treat an inherited retinal disease, indicated for children and adults with vision loss caused by mutations in both copies of the RPE65 gene and sufficient [...]
European Commission Approves Spark Therapeutics’ LUXTURNA® (voretigene neparvovec), a One-time Gene Therapy for Inherited Retinal Disease Caused by Confirmed Biallelic RPE65 Mutations
23/11/2018
LUXTURNA is first gene therapy for a genetic disease approved in both the U.S. and EU LUXTURNA is first and only gene therapy approved in EU for patients with an inherited retinal disease (IRD) Spark Therapeutics will [...]
Curetis Accelerates 510(k) Submission Preparation for Unyvero LRT in BAL Specimen Based on Positive FDA Feedback
23/11/2018
Curetis Accelerates 510(k) Submission Preparation for Unyvero LRT in BAL Specimen Based on Positive FDA Feedback U.S. FDA and Curetis agree on 510(k) requirements for clearing BAL as additional sample type for Unyvero [...]
Sensorion Enters Into Exclusive Negotiations with Pasteur Institute for Hearing Loss Gene Therapy Programs
23/11/2018
MONTPELLIER, France, Nov. 23, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN / PEA-PME eligible) announced today that it has entered into a letter of intent with Pasteur Institute (Paris, France) to [...]
Nova Leap Health Corp. Reports Third Quarter 2018 Financial Results and Provides Corporate Update
23/11/2018
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Nov. 22, 2018 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a [...]

Pages